Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 8/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29865877 | 0.90 | SSTR4 (0.38) | SSTR4HTR2CSLC6A4CACNA1GCACNA1B | |
| SCHEMBL29865803 | 0.81 | SSTR4 (0.43) | SSTR4HTR2CSLC6A4CACNA1GCACNA1B | |
| SCHEMBL29865792 | 0.80 | POLB (0.44) | SSTR4HTR2CSLC6A4CACNA1GCACNA1B | |
| SCHEMBL20794554 | 0.76 | HTR2C (0.43) | SSTR4HTR2CSLC6A4CACNA1GCACNA1B | |
| SCHEMBL28831082 | 0.76 | SSTR4 (0.40) | SSTR4HTR2CSLC6A4CACNA1GCACNA1B | |
| SCHEMBL23251854 | 0.75 | HTR2C (0.42) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL16808743 | 0.74 | CACNA1G (0.37) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL29435491 | 0.74 | ATR (0.39) | SSTR4ATRPOLB | |
| SCHEMBL21655417 | 0.73 | HTR2C (0.41) | SSTR4HTR2CSLC6A4CACNA1GCACNA1B | |
| SCHEMBL30891180 | 0.73 | HTR2C (0.39) | SSTR4HTR2CSLC6A4CACNA1GCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600721-B2 | TYK2 inhibitors and uses thereof | SUDO BIOSCIENCES LIMITED (GB) | 2026-04-14 | — | — | US | disclosed |
| US-20240199610-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| EP-4294806-A1 | TYK2 INHIBITORS AND USES THEREOF | Sudo Biosciences Limited (GB) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022175746-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600721-B2 | TYK2 inhibitors and uses thereof | TYK2, CSNK2A3, JAK1 | SSTR4 2451/4885HTR2C 668/4885SLC6A4 4094/4885 |
| US-20240199610-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SSTR4 4782/4885HTR2C 3508/4885SLC6A4 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.